What stock did Claude AI buy first?

Claude's first trade was buying 129 shares of Vanda Pharmaceuticals (VNDA) at $7.82, targeting an FDA catalyst on February 21, 2026 for Bysanti (bipolar I disorder and schizophrenia).

Why did the AI pick VNDA stock?

Claude identified VNDA for its asymmetric risk/reward: a binary FDA decision on February 21, recent Nereus approval momentum, analyst targets of $13-22 vs. $7.82 entry, and small market cap that moves hard on news.

What is the VNDA FDA catalyst?

Vanda Pharmaceuticals has a PDUFA date of February 21, 2026 for Bysanti (milsaperidone), an NDA for bipolar I disorder and schizophrenia. Approval could send the stock significantly higher.

AI Stock Experiment Day 1: Claude Buys VNDA | Best or Worst Idea

Day 1: The AI Makes Its First Move

January 30, 2026 · Day 1 of 90

Following along? I'm running this experiment in Robinhood — commission-free stocks and options. Sign up here and get a free stock.

What Happened Today

Day 1. The experiment is live.

This morning I checked in with Claude at 7:10 AM Mountain to get my marching orders. After scanning FDA catalysts, biotech momentum plays, short squeeze setups, and options flow, Claude identified its first high-conviction trade.

At market open, I executed.

The Trade

Action	Ticker	Shares	Price	Total
BUY	VNDA	129	$7.82	$1,008.78

Claude's Thesis: Why VNDA?

Vanda Pharmaceuticals (NASDAQ: VNDA) is a small-cap biopharma with a binary FDA catalyst in 22 days.

The Catalyst: February 21, 2026 — FDA PDUFA date for Bysanti (milsaperidone), an NDA for bipolar I disorder and schizophrenia
Recent Win: Nereus (tradipitant) approved December 30 for motion sickness — first new treatment in 40+ years
Analyst Targets: $13 to $22 vs. our $7.82 entry — 66% to 181% upside
Small Cap: ~$415M market cap — moves hard on news
Asymmetric Risk/Reward: 50-80% upside on approval, 20-35% downside on rejection

This is a classic binary biotech setup: defined catalyst, clear timeline, and significant price dislocation if the event goes our way.

The Game Plan

Claude set clear rules for managing this position:

Quick pop (+10% in 1-2 days): Sell immediately, rotate into next play
Hits $10.50 before Feb 10: Auto-sells via limit order (+34%), we rotate
No early pop: Hold into Feb 21 PDUFA, potentially add options to amplify gains

I set a sell limit order at $10.50 as an "auto-take-profit" in case the stock runs fast. If it doesn't trigger by Feb 10, I'll cancel it and let the position ride into the FDA decision.

Current Position

Ticker	Shares	Entry	Current	Value	P&L
VNDA	129	$7.82	$7.83	$1,010.07	+$1.29 (+0.13%)

Key Dates to Watch

Date	Event	Action
Feb 10	Day before VNDA earnings	Reassess — hold or trim?
Feb 11	VNDA Q4 2025 Earnings	Monitor reaction
Feb 20	Day before PDUFA	Final decision — add options?
Feb 21	Bysanti FDA Decision	The catalyst

Scoreboard

Starting Capital	$1,000.00
Current Value	$1,010.07
Today's P&L	+$1.29
Total Return	+1.01%
Day	1 of 90

What's Next

Monday I check back in with Claude at 7:10 AM Mountain. We'll review any weekend news, check the pre-market, and decide if we hold, add, or rotate.

The position is on. The clock is running.

89 days to go.

Want to try this yourself? I'm using Robinhood for commission-free trading. Sign up with my link and we both get a free stock.

Disclaimer: This is a personal experiment for entertainment and educational purposes, not financial advice. Trading stocks and options involves significant risk — you can lose some or all of your money. I am not a licensed financial advisor. Do your own research before making any investment decisions. Past performance does not guarantee future results. If you sign up for Robinhood using my link, I may receive a referral bonus at no cost to you.

Day 1